Fiducial Placement for Stereotactic Body Radiation Therapy under Only Endoscopic Ultrasonography Guidance in Pancreatic and Hepatic Malignancy: Practical Feasibility and Safety.
- Author:
Jun Ho CHOI
1
;
Dong Wan SEO
;
Do Hyun PARK
;
Sung Koo LEE
;
Myung Hwan KIM
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. dwseoamc@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Fiducial markers;
Endosonography;
Radiosurgery;
Pancreatic neoplasms;
Liver neoplasms
- MeSH:
Aged;
Aged, 80 and over;
Endosonography/*methods;
Equipment Design;
Feasibility Studies;
Female;
*Fiducial Markers;
Humans;
Liver Neoplasms/*radiotherapy/ultrasonography;
Male;
Middle Aged;
Needles;
Pancreatic Neoplasms/*radiotherapy/ultrasonography;
Radiosurgery/*methods;
Treatment Outcome
- From:Gut and Liver
2014;8(1):88-93
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Stereotactic body radiation therapy (SBRT) for gastrointestinal malignancies requires the placement of fiducials to guide treatment delivery. This study aimed to determine the safety and technical feasibility of endoscopic ultrasonography (EUS)-guided fiducial placement for SBRT. METHODS: From November 2010 to August 2012, 32 consecutive patients who were scheduled to receive SBRT for pancreatic and hepatic malignancies were referred for EUS-guided fiducial placement. Primary outcome measurements included technical success, the fiducial migration rate, and procedural complications. RESULTS: All 32 patients had successful fiducial placement under EUS guidance. The mean number of fiducials placed per patient was 2.94+/-0.24 (range, 2 to 3 seeds). Spontaneous fiducial migration was noted in one patient (3.1%). Of the 32 patients with fiducials placed, 29 patients (90.6%) successfully underwent SBRT. One patient (3.1%) developed mild pancreatitis, requiring a 2-day prolonged hospitalization after fiducial placement. Five patients (15.6%) underwent same-session, EUS-guided fine needle aspiration for histologic confirmation at the time of fiducial placement, without any procedure-related complication. CONCLUSIONS: EUS-guided fiducial placement is a safe and technically feasible technique for preparing patients with both pancreatic and hepatic malignancies for SBRT. The fiducial markers facilitate safe and accurate targeting of the tumor during SBRT.
